Messages people are sending
These are real letters, emails, and call scripts that supporters wrote and then chose to share with us. Every one is published with its author's permission and only after a person reviewed it. Nothing written with the tools on this site reaches us unless its author ticks a box and presses send.
Email Alex Scheffler, Omaha, NE
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Omaha, Nebraska. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Omaha, Nebraska. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. Please Delay or narrow the emergency scheduling of SR-17018 specifically. Separate SR-17018 from other listed compounds and review it on its own merits. Publish the compound-specific evidence being relied upon. Preserve lawful research and medical-development access to SR-17018. Involve HHS/FDA scientific and medical review before any placement. Avoid blocking potential opioid-withdrawal research before it can be studied. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do. Sincerely, Alex Scheffler 2339 BENSON GARDENS BLVD Omaha, Nebraska 68134 alexschefflerincarnate@gmail.com 14026868015 Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email Brian Keith Lauterbach, Plano, TX
Subject: Please preserve research access to SR-17018 — a constituent in recovery
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from Plano, Texas. This issue is personal to me: my own health and recovery are affected by whether compounds like this can be studied and, if warranted, developed through lawful medical channels. Scaremongering does not work, placing this substance in Schedule 1 prior to giving it a chance to be studied and used to help those of us in chronic pain where applicable. This proposed ban looks to do much more harm than good and I am quite sure that the lawmakers have no idea what is about to happen when this takes effect and the outcome has more risks than benefit to the general public. Please overlook the greedy lobby and consider your constituents that need your help right now. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Email Anonymous — CA
Subject: Concerns about overbroad emergency scheduling of SR-17018
I am writing about the Drug Enforcement Administration's temporary scheduling notice involving SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine). I am asking you to help ensure this compound is studied before it is placed into Schedule I. I am a constituent writing from [city withheld], California. I am concerned that bundling SR-17018 into a broad emergency scheduling action, without compound-specific evidence and without HHS/FDA scientific review, is an overbroad use of emergency authority that can foreclose promising research before the public-health value is understood. Many people report that SR-17018 may have helped them reduce opioid use with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research and compound-specific review rather than emergency prohibition. Specifically, I urge you to: • Delay or narrow the emergency scheduling of SR-17018 specifically. • Separate SR-17018 from other listed compounds and review it on its own merits. • Publish the compound-specific evidence being relied upon. • Preserve lawful research and medical-development access to SR-17018. • Involve HHS/FDA scientific and medical review before any placement. • Avoid blocking potential opioid-withdrawal research before it can be studied. This request is not for unregulated sales and does not involve any sourcing, dosing, or vendor information. It is a request to preserve a lawful research and medical-development pathway during an opioid crisis in which more withdrawal-treatment options are badly needed. Thank you for your attention to this issue. I would appreciate a written response describing what your office can do.
Shared with permission and reviewed before publication. Authors who shared anonymously are shown only by state — their name and city were removed in their own browser and never sent to us. If you shared a message and want it taken down, ask us to delete it; our privacy policy explains what we keep.